晚期非小细胞肺癌组织中BRCA1、STMN1、RRM1的表达及其临床意义

目的：探讨晚期非小细胞肺癌（NSCLC）组织中DNA修复基因家族成员BRCA1、STMN1、RRM1的表达及其临床意义。方法：回顾性分析本院2009年1月至2012年1月86例经组织学或细胞学证实的IIIB／IV期非小细胞肺癌患者，以分支DNA-液相芯片法检测肿瘤标本的BRCA1、STMN1、RRM1基因mRNA表达，并对检测结果应用SPSS13．0进行统计分析。结果：BRCA1中高表达与患者的性别无明显相关性（x毫0．1003，P=0．7514），STMN1中高表达与肿瘤的分化程度相关（卡方=18．3002，P=0．000）。分析基因mRNA的表达情况与患者的化疗有效率，提示BRCA1中高表达患者完全缓解0例、部分缓解23例、稳定17例、进展16例，低表达患者分别为0例、12例、14例、4例（P〉0．05），而STMN1表达阳性患者与阴性患者的临床疗效分别为0例、14例、21例、16例和0例、21例、10例、4例（P〈0．05）；RRM1表达阳性患者与阴性患者的临床疗效分别为0例、17例、19例、20例和0例、18例、12例、0例（P〈0．05）。结论：通过对BRCA1、STMN1、RRM1基因mRNA表达的个体化治疗靶标检测，对患者的预后以及化疗疗效有一定的预测价值。

BRCA1, STMN1, RRM1 Expression and its Clinical Significance in Advanced Non-Small Cell Lung Cancer Patients

Objective： To investigate the organization of advanced non-small cell lung cancer （NSCLC） and its clinical significance of the DNA repair gene family members BRCA1, STMN1, RRM1. Methods： Were analyzed retrospectively from January 2009 to January 2012 86 patients with histologically or cytologically confirmed 11113 of/IV non-small cell lung cancer patients, their tumor specimens to the the branch DNA-liquid chip law individualized therapeutic target detection, detection of BRCA1, STMN1, RRM1 rnRNA expression, and test results application SPSS 13.0 statistical analysis. Results： Of BRCA1 in the high expression of the patient＇s gender have significant correlation between high-expression with the patient＇s gender significant correlation （chi-square = 0.1003, P-=0.7514）, STMN1 in high expression with tumor of the differentiation of the degree associated （card square = 18.3002, P= 0.000）. Of BRCA1 expression in the case of patients with chemotherapy efficiency no obvious correlation between the expression of the situation with the patient＇s chemotherapy have efficiency analysis, prompt, high expression 0 cases of complete remission, part remission 23 cases, stable progress in 17 cases of 16 cases, patients with low expression group were 0 cases, 12 cases, 14 cases, and four cases （P〉 0.05）, while RR M1STMN1, as well STMN1 expression-positive patients and negative patients in clinical efficacy were 0 cases, 14 cases, 21 cases and 16 eases of 0 cases, 21 cases, 10 cases, 4 cases （P 〈0.05）; RRM1 expression in patients with positive and negative patients in clinical effica- cy were 0 cases, 17 cases, 19 cases and 20 cases of 0 cases, 18 cases, 12 cases, 0 （P 〈0.05）. Conclusion： Individualized treatment targets mRNA expression of BRCA 1, STMN1, RRM 1 gene detection, prognosis, and chemotherapy patients have some predictive value.